Related Experiment Video

Updated: Aug 10, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents

Apurva A Desai1, Walter M Stadler

  • 1Department of Medicine, The University of Chicago, IL 60637, USA. adesai@medicine.bsd.uchicago.edu

Current Urology Reports
|February 17, 2006
PubMed

Insights

Newer non-cytotoxic cancer drugs, like those for renal cell carcinoma, present unique development challenges. Adapting traditional drug development methods is crucial for advancing these targeted therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Neoplastic Diseases

Background:

  • Expanding knowledge of neoplastic diseases yields novel drug targets.
  • Renal cell carcinoma (RCC) serves as a key example for targeted therapy development.
  • Initial experiences highlight unique challenges with molecularly targeted agents.

Purpose of the Study:

  • To discuss recent data from renal cell carcinoma (RCC) trials.
  • To identify challenges in developing non-cytotoxic agents.
  • To propose modifications for traditional drug development concepts.

Main Methods:

  • Review of recently reported data from RCC trials.
  • Analysis of putative cytostatic agents in clinical development.
  • Discussion of issues in various phases of clinical development.

Main Results:

  • Non-cytotoxic agents require modified drug development approaches.
  • Efficient development necessitates addressing specific challenges.
  • Early trials in RCC inform future therapeutic strategies.

Conclusions:

  • Drug development for targeted therapies, especially non-cytotoxic agents, needs innovation.
  • Adapting traditional methods is essential for advancing cancer drug development.
  • Further research and strategic planning are vital for cytostatic agent development in RCC and other cancers.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...